c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy
Authors:
- 1 January 2007
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 9 (2) , 102-108
Abstract
Receptor tyrosine kinases have come to fruition as therapeutic targets in a variety of malignancies. In this group of targets, the c-Met receptor tyrosine kinase plays an important role in increased cell growth, reduced apoptosis, altered cytoskeletal function, increased metastasis, and other biologic changes. The ligand for c-Met is hepatocyte growth factor (HGF), also known as scatter factor. Met is overexpressed and mutated in a variety of malignancies, among which germline mutations are of particular interest. Most mutations of Met have been found in the juxtamembrane, the tyrosine kinase, and the semaphorin domain. Met gain-of-function mutations lead to deregulated or prolonged tyrosine kinase activity, which is instrumental to its transforming activity. This review summarizes the biologic functions regulated by Met and its structural requirements as well as related developments in targeted therapy. Treatment approaches, including antagonism of HGF binding to Met, targeting of RNA and the Met protein, and inhibition of the tyrosine kinase domain of Met, are highlighted. Targeting of the HGF/Met pathway, alone or in combination with standard therapies, is likely to improve current therapies in Met-dependent malignancies.Keywords
This publication has 74 references indexed in Scilit:
- A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivoClinical Cancer Research, 2006
- Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancerCarcinogenesis, 2005
- RNA Interference Reveals that Ligand-Independent Met Activity Is Required for Tumor Cell Signaling and SurvivalCancer Research, 2004
- The Semaphorin 4D receptor controls invasive growth by coupling with MetNature Cell Biology, 2002
- Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma developmentOncogene, 2001
- c-MET Expression in MyofibroblastsThe American Journal of Pathology, 2001
- A novel germ line juxtamembrane Met mutation in human gastric cancerOncogene, 2000
- The HGF receptor family: unconventional signal transducers for invasive cell growthGenes to Cells, 1996
- Purification and subunit structure of hepatocyte growth factor from rat plateletsFEBS Letters, 1987
- Scatter factor is a fibroblast-derived modulator of epithelial cell mobilityNature, 1987